Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9797MR)

This product GTTS-WQ9797MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9797MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15963MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ11392MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ15560MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ12707MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ10998MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ4540MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ13992MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ14852MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-CD33A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW